Could a common statin shield heart health in rare blood vessel disease?
NCT ID NCT02117453
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This study tested whether rosuvastatin, a cholesterol-lowering drug, can reduce early signs of artery hardening and prevent heart attacks or strokes in people with ANCA-associated vasculitis. 121 adults in remission from vasculitis were randomly assigned to take rosuvastatin or a placebo for up to 2 years. The main goal was to see if the drug slowed thickening of the carotid artery wall, a marker of heart disease risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED PRIMARY NECROTIZING VASCULITIDES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hopital Cochin
Paris, 75014, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rosuvastatin
What this could lead to
If it works, this could show that a common cholesterol drug helps protect blood vessels and reduce heart problems in people with vasculitis.
What could go wrong
This is a completed Phase 3 trial, but statins are already widely used; the added benefit for vasculitis patients may be small or not significant. Results may not change current practice.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.